Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03455491
Other study ID # ARI-XC221-02
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date February 12, 2018
Est. completion date June 28, 2018

Study information

Verified date October 2019
Source PHARMENTERPRISES LLC
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A multicenter double-blinded, randomized, placebo-controlled, parallel-group comparative Phase II clinical study to assess safety, tolerability, efficacy and optimal dose of XC221 vs. placebo in patients with uncomplicated influenza or other ARVI during a 3-day treatment.

The primary objective of the study is to demonstrate the difference in time before the onset of a sustained improvement in clinical symptoms according to the Modified Jackson Scale for ARVI and to determine the optimal dose of XC221 in the treatment of influenza and other ARVI.


Description:

11 Russian centers were planned for participation in this study. The study consists of three periods: screening, treatment and follow-up.

All eligible patients will be randomized into 3 groups (groups A, B and C) in a 1:1:1 ratio:

Group A - XC221 100 mg daily (40 patients); Group B - XC221 200 mg daily (40 patients); Group C - Placebo (40 patients).

During the treatment period (3 days), patients will receive XC221 / placebo daily on a background of standard symptomatic therapy. The follow-up period lasts for 11 days.


Recruitment information / eligibility

Status Completed
Enrollment 120
Est. completion date June 28, 2018
Est. primary completion date June 28, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria:

1. Men and women aged 18 to 45 years (inclusively).

2. Clinically diagnosed influenza or ARVI.

3. Patient's body temperature =37.5º? and at least 1 symptom from Modified Jackson Scale estimated more than 2 points.

4. Uncomplicated course of influenza or ARVI based on clinical estimations.

5. The first 36 hours from the beginning of symptoms of influenza or ARVI.

6. Women of reproductive age (who are not in menopause and who have not undergone surgical sterilization) and men who have sexual activity should use a reliable method of contraception (acceptable methods of contraception in this study are: intrauterine devices, oral contraceptives, contraceptive patch, long-acting injectable contraceptives, a double barrier method (condom and diaphragm with spermicide) throughout the study period.

7. Compliance with the treatment regimen, visits and laboratory examinations provided by the protocol.

8. Signed Informed Consent Form.

Exclusion Criteria:

1. Existence of complications of influenza or ARVI (including the presence / development of bacterial infection).

2. Hypersensitivity to excipients of the drug XC221 or placebo.

3. Antiviral medications in 7 days prior to screening (antiviral agents, interferons and interferon inducers, drugs that have immunomodulating action) or anti-infective agents of systemic or local action.

4. Severe infection with signs of cardiovascular insufficiency development and other manifestations of infectious-toxic shock, as well as with the presence of neuroinfection syndrome (encephalic and meningoencephalic reactions, polyradiculoneuritis, neuritis).

5. Signs of the development of viral pneumonia (the presence of two or more of the following symptoms): dyspnea, chest pain when coughing, systemic cyanosis, dullness of percussion sound with a symmetrical evaluation of the upper and lower sections of the lungs).

6. Infectious diseases during the last week before including into the study.

7. History of bronchial asthma.

8. History of increased convulsive activity.

9. Severe, decompensated or unstable somatic diseases (any diseases or conditions that are life-threatening or may worsen the patient's prognosis, and make him/her ineligible for the clinical study).

10. History of oncological diseases, HIV, tuberculosis.

11. Diabetes mellitus.

12. Drug or alcohol abuse.

13. Participation in any other clinical trial in the last 90 days.

14. Pregnancy or lactation.

15. Military or prison populations.

16. Impossibility or inability to comply with the study procedures.

17. A member of the investigator's family or other person interested in the results of the study.

18. Abnormal laboratory results, which, according to the study doctor, interfere with the patient's inclusion in the study.

19. History of renal insufficiency.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
XC221 100 mg
once daily during 3 days.
XC221 200 mg
once daily during 3 days.
Placebo
once daily during 3 days.

Locations

Country Name City State
Russian Federation City Clinical Hospital ?9 Izhevsk
Russian Federation Kuban State Medical University Krasnodar
Russian Federation City Clinical Hospital ?1 n.a. Semashko Rostov-on-Don
Russian Federation Ryazan State Medical University n.a. Pavlov Ryazan'
Russian Federation City Clinical Hospital ?40 of Kurortny District Saint Petersburg
Russian Federation Research Institute of Influenza Saint Petersburg
Russian Federation The Center for Prevention and Fight about AIDS and Infectious Diseases Saint Petersburg
Russian Federation The Consulting and Diagnostic Center with out-patient help of the Administration of the President of the Russian Federation Saint Petersburg
Russian Federation Mordovia State Medical University n.a. N.P.Ogarev, Clinical site - Republic Infectious Clinical Hospital Saransk
Russian Federation Volgograd State Medical University, Clinical site - Infectious Regional Clinical Hospital ? 1 Volgograd
Russian Federation ?linical Hospital ?3 Yaroslavl

Sponsors (1)

Lead Sponsor Collaborator
PHARMENTERPRISES LLC

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type Measure Description Time frame Safety issue
Primary Time to Sustained Improvement in Clinical Symptoms Based on Modified Jackson Scale for ARVI The time before the onset of sustained improvement in clinical symptoms according to the Modified Jackson Scale (no more than 1 point for each symptom), measured in hours from the moment of the first dose of the drug.
Modified Jackson Scale measures individuals' subjective ratings the severity of 12 respiratory symptoms. Ranges for each symptom: 0 points (no symptoms) - 3 points (the most severe). Total score (ranges from 0 to 32 points) is a sum of the point for each symptom.
From the time of randomization up to Day 14
Secondary Time to Body Temperature Normalization Time to body temperature normalization since treatment initiation, measured in hours (normalization is regarded as setting of body temperature below 37°C without elevation above these values) From the time of randomization assessed up to Day 14
Secondary Percentage of Patients With Complications The percentage of patients with complications of influenza/acute viral URI From the time of randomization up to Day 14
Secondary The Area Under the Curve "Modified Jackson Scale Score" During 3-day Therapy Modified Jackson Scale measures individuals' subjective ratings the severity of 12 respiratory symptoms. Ranges for each symptom: 0 points (no symptoms) - 3 points (the most severe). Total score (ranges from 0 to 32 points) is a sum of the point for each symptom. From randomization up to 3 days of treatment
See also
  Status Clinical Trial Phase
Completed NCT05523089 - The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults Phase 2
Completed NCT05009251 - Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake N/A
Completed NCT03282240 - Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US Phase 3
Completed NCT00968539 - Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults Phase 3
Completed NCT00971425 - Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1) Phase 3
Completed NCT00968526 - Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults Phase 3
Completed NCT05525494 - Patient Portal Flu Vaccine Reminders (5) N/A
Completed NCT04074928 - Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects Phase 3
Completed NCT04695717 - This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam Phase 3
Completed NCT05012163 - Lottery Incentive Nudges to Increase Influenza Vaccinations N/A
Completed NCT04109222 - Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively Phase 4
Completed NCT03888989 - Response to Influenza Vaccine During Pregnancy Phase 1
Completed NCT02587221 - Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age Phase 3
Completed NCT03453801 - The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection Phase 1
Completed NCT01440387 - A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older Phase 3
Terminated NCT01195779 - Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children Phase 2
Completed NCT03321968 - Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults Phase 3
Completed NCT00972517 - Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children Phase 3
Completed NCT04570904 - Broadening Our Understanding of Early Versus Late Influenza Vaccine Effectiveness
Recruiting NCT03331991 - Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel N/A